What are the possible adverse reactions to chemotherapy for the treatment of Burkitt lymphoma/Burkitt-like lymphoma (BL/BLL)?

Updated: Dec 20, 2019
  • Author: Ali H Kanbar, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Each of the above mentioned regimens carries a 60-70% chance of prolonged progression-free and overall survival, but that is unfortunately associated with a significant toxicity profile. No toxic deaths were reported in the initial study by Magrath (CODOX-M/IVAC), but the rate of grade 3/4 neutropenia was 100%; thrombocytopenia, 96%; mucositis, 61%; and sepsis, 22%. Similar toxicities were seen on the CALGB 9251 protocol.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!